Skip to main content

Several UNC Lineberger members and UNC School of Medicine faculty presented at the American Society of Hematology (ASH) Annual Meeting in San Francisco last week. With more than 15,000 members from nearly 100 countries, ASH is the world’s largest professional society serving clinicians and scientists around the world who are working to conquer blood diseases. The 56th ASH Annual Meeting & Exposition is the premier event in malignant and non-malignant hematology.


Kenneth Ataga, MBBS, will present “Pulmonary hypertension in sickle cell disease: diagnosis and management.” He will also present three posters:

  1. “NKTT120 reduces iNKT cells without dose limiting toxicity in stable adult sickle cell patients in a phase 1 trial;”
  2. “Genes Associated with Survival in Adult Sickle Cell Disease” and
  3. “Hypercoagulability in Sickle Cell Disease: The importance of the cellular component of blood.”

Wolfgang Bergmeier, PhD, will present “Premature platelet activation and resistance to P2Y12 inhibitors in Rasa 3 mutant mice.” He will also present the poster “Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic-plug composition.”

Matt Foster, MD, will present “796 Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403.”

Satish Gopal, MD, MPH, will present the poster, “Antiretroviral therapy has equalized presentations and short-term outcomes between HIV+ and HIV- lymphoma patients in Lilongwe, Malawi.”

Raj Kasthuri, MBBS, MD, will present the poster “Effect of gernotype and antifibronolytic therapy on the severity of epistaxis in Hereditary Hemorrhagic Telangiectasia.”

Nigel Key, MD, will lead an educational/scientific session entitled “Comeback Kid: The Contact Pathway and Factor XI: Epidemologic and Clinical Data Linking Factors XI and XII to Thrombosis.” He will also present the poster “In vitro characterization of a homogenous low-molecular weight heparin with reversible anticoagulant activity.”

Nigel Mackman, PhD, will lead a special symposium on basic science of hemostasis and thrombosis and present five posters:

  1. “Role of the Thrombin-PAR-1 pathway in Coxsackievirus induced hepatitis;”
  2. “Role of Tissue Factor in Mycobacterium Tuberculosis-induced inflammation and disease pathogenesis;”
  3. “Alternatively Spliced Tissue Factors as a new therapeutic target in pancreatic cancer;”
  4. “Impaired hemostasis caused by deficit of tissue factor-triggered blood coagulation leads to alveolar hemorrhages and increased mortality in Influenza A infection” and
  5. “The tissue factor/thrombin/protease-activated receptor 1 pathway enhances double-strand RNA induced immune responses in macrophages.”

Stephan Moll, MD, will present “New insights into treatment of venous thromboembolism.”

Steven Park, MD, will present “Brentuximab Vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin Lymphoma: Long Term Outcomes.” He will also present three posters:

  1. “A phase 2 trial of induction chemotherapy with ABVD followed by Brentuximab Vedotin Consolidation in patients with previously untreated non-Bulky Stage I or II Hodgkin Lymphoma;”
  2. “Unexpected and serious toxicity observed with combined idealalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphoma: Alliance A051201/A05102” and
  3. “Patient characteristics and initial treatment pattern in the United States for the most common subtypes of peripheral T-cell lymphoma.”

Jonathan Serody, MD, will present the poster “Plasticity of Th17 cells and conversion to Th1 cells during acute GVHD.” He will also give three presentations:

  1. “Infusion of ex vivo activated donor type 2 innate lymphoid cells inhibit Th1 activity and reduces acute GVHD;”
  2. “Targeting BCL6 and Germinal Centers in Chronic GVHD Using Direct and Epigenomic Therapies” and
  3. “A selective and potent ROCK2 inhibitor (KD025) decreases human STAT3-dependent IL-21 and IL-17 production and experimental chronic GVHD.”

Thomas Shea, MD, will present “CALGB 100801: A phase II multi-center NCI cooperative group study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia and older patients with AML: Results of a test-dose strategy to target busulfan exposure.” He will also present the poster “Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: Updated results.”

Hank Van Deventer, MD, will present the poster “The contribution of fibrocytes to the progression of multiple myeloma.”

Peter Voorhees, MD, will present four posters:

  1. “Determination of the MTD and encouraging results in an ongoing open-label phase 1/2a study of the safety and efficacy of Melflufen and Dexamethasone in combination for patients with relapsed and relapsed/refractory multiple myeloma;”
  2. “An open-label dose escalation, multi-center Phase 1 study of PRLX 93936, an agent synthetically active against the activated RAS pathway, in the treatment of relapsed or relapsed and refractory multiple myeloma;”
  3. “Oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Initial results from the dose escalation portion of a Phase 1b/2 multicenter, open-label study” and
  4. “Riconlinostat (ACY-1215) a selective HDAC6 inhibitor, in combination with lenalidomide and dexamethasone: Results of a Phase 1b trial in relapsed and relapsed refractory multiple myeloma.”

William Wood, MD, will present the poster “Interval exercise training is feasible and may improve cardiorespiratory performance prior to hematopoietic cell transplantation.” He will also give two presentations entitled “Patient-reported quality of life is an independent predictor of survival after allogeneic hematopoietic cell transplantation: A secondary analysis form the Blood and Marrow Transplant Clinical Trials Network 0902” and “Do hematopoietic cell transplant patients treated on a clinical trial do better: Comparison of characteristics and outcomes of patients enrolled versus not enrolled on blood and marrow transplant clinical trials network 0201.”

Josh Zeidner, MD, will present two posters “A comprehensive assessment of phase 1 clinical studies in acute myeloid leukemia” and “Characterization of Immune evasion mechanisms at diagnosis and after chemotherapy in patients with acute myeloid leukemia.”